Articles
Brain Metastases Research Articles 2026
Jan 5, 2026
Leptomeningeal Disease: When treating breast cancer that’s spread to the cerebrospinal fluid, proton therapy controlled the cancer better than traditional X-ray radiation
Jan 9, 2026
Trojan horses at leptomeningeal cellular gates: Antibody–drug conjugates deliver cytotoxic payloads
Jan 27, 2026
Recent Advances in Systemic Treatment for HER2-Negative Breast Cancer with Brain Metastases
Feb 9, 2026
Proactive brain screening using contrast-enhanced brain CT scans in HER2+ metastatic breast cancer
Feb 19, 2026
Treatment for Brain Metastases With Stereotactic Radiation
vs Hippocampal-Avoidance Whole Brain Radiation (plain language summary)
Treatment for Brain Metastases With Stereotactic Radiation
vs Hippocampal-Avoidance Whole Brain Radiation (PDF)
March 4, 2026
Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study)
March 7, 2026
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis
March 18, 2026
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results
Brain Metastases Research Articles 2025
Jan 10, 2025
The DEBBRAH trial: Trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer patients with leptomeningeal carcinomatosis
Jan 15, 2025
Brain Metastases in Breast Cancer
Jan 24, 2025
Phase II trial of brain MRI surveillance in stage IV breast cancer
March 6, 2025
Association Between Human Epidermal Growth Factor Receptor 2-Low Status and Time to Development of Brain Metastases Among Patients With Breast Cancer: A Retrospective Cohort Study
March 8, 2025
Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases
March 28, 2025
Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases from a large registry of BMBC
March 31, 2025
Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients
April 24, 2025
Intrathecal administration of PD-1 inhibitor combined with pemetrexed for leptomeningeal metastases from breast cancer: a case report
May 30, 2025
Patritumab deruxtecan in leptomeningeal metastatic disease of solid tumors: the phase 2 TUXEDO-3 trial
June 26, 2025
Utidelone Plus Bevacizumab for ERBB2-Negative Metastatic Breast Cancer and Active Brain Metastases
The U-BOMB Phase 2 Nonrandomized Clinical Trial
July 1, 2025
A triple-punch approach: methionine restriction enhances combination inhibitors in brain metastatic triple-negative breast cancer
July 15, 2025
Clinical–pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study
July 21, 2025
Trastuzumab deruxtecan in patients with active brain metastases from HER2- positive/low metastatic breast cancer: a retrospective multicenter real-world study
Sept 4, 2025
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis
Sept 11, 2025
Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World Study
Oct 15, 2025
Brain Imaging Screening in Metastatic Breast Cancer: Is It Time to Rethink Clinical Guidelines and Practice?
Oct 28, 2025
Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study
Nov 5, 2025
Safety and feasibility of Ommaya reservoir for intrathecal chemotherapy in patients with leptomeningeal disease
Nov 11, 2025
Prognostic scores for patients with multiple brain metastases treated with repeated stereotactic radiosurgery − a secondary analysis of the CYBER-SPACE randomized phase 2 trial
Nov 26, 2025
Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of breast cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial
Brain Metastases Research Articles 2024
Jan 4, 2024
Brain Radiotherapy With Pyrotinib and Capecitabine in Patients With ERBB2-Positive Advanced Breast Cancer and Brain MetastasesA Nonrandomized Phase 2 Trial
Feb 1, 2024
New insights into HER2-low breast cancer brain metastasis: A retrospective analysis
April 1, 2024
Local hero: A phase II study of local therapy only (stereotactic radiosurgery and / or surgery) for treatment of up to five brain metastases from HER2+ breast cancer. (TROG study 16.02)
April 29, 2024
Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis
May 15, 2024
Breast Cancer Brain Metastasis: A Comprehensive Review
May 30, 2024
Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy
June 13, 2024
Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis
June 18, 2024
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study
June 21, 2024
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions
July 4, 2024
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases
July 6, 2024
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 0225
August 2, 2024
Impact of systemic disease on CNS disease control after stereotactic radiosurgery to breast cancer brain metastases (The SYBRA Study)
August 30, 2024
Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival
Sept 20, 2024
A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer
Sept 27, 2024
ESMO 2024: T-DXd Yields Significant Intracranial Response in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
Sept 30, 2024
Brain Metastasis in Triple-Negative Breast Cancer
Oct 10, 2024
Development of graded prognostic assessment for breast Cancer brain metastasis incorporating extracranial metastatic features: a retrospective analysis of 284 patients
Oct 17, 2024
Real-world outcomes in patients with brain metastases secondary to HR+/HER2− MBC treated with abemaciclib and local intracranial therapy
Nov 1, 2024
Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022
Brain Metastases Research Articles 2023
Jan 4, 2023
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Jan 5, 2023
Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases
Jan 22, 2023
Systematic Review The Evolving Landscape of Leptomeningeal Cancer from Solid Tumors: A Systematic Review of Clinical Trials
Feb 2023
Multidisciplinary Management of Brain Metastasis from Breast Cancer
Feb 1, 2023
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Feb 6, 2023
Multidisciplinary Management of Brain Metastasis from Breast Cancer
Feb 20, 2023
Epidemiology, clinical outcomes, and unmet needs of patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases: A systematic literature review
Feb 21, 2023
Nicole Fleege, MD, and Aki Morikawa, MD, on Coordinated Care for Breast Cancer Patients With CNS Metastasis
March 1, 2023
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics
March 30, 2023
Durable responses in patients with HER2+ breast cancer and leptomeningeal metastases treated with trastuzumab deruxtecan
April 7, 2023
High-dimensional immune cell profiling of cerebrospinal fluid from patients with metastatic breast cancer and leptomeningeal disease
April 14, 2023
I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
April 19, 2023
Utilizing cell-free DNA to predict risk of developing brain metastases in patients with metastatic breast cancer
May 1, 2023
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
May 1, 2023
Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries
May 24, 2023
Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer
August, 14, 2023
Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases
August 15, 2023
Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
August 15, 2023
Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
August 17, 2023
Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study
Oct 11, 2023
Treatment with trastuzumab deruxtecan in patients with HER2-positive breast cancer and brain metastases and/or leptomeningeal disease (ROSET-BM)
Oct 23, 2023
Incidence of HER2-expressing brain metastases in patients with HER2-null breast cancer: a matched case analysis
Nov 17, 2023
Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data
Nov 25, 2023
Brain Metastases in the Setting of Stable Versus Progressing Extracranial Disease Among Patients With Metastatic Breast Cancer
Dec 21, 2023
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast CancerA Randomized Clinical Trial
Brain Metastases Research Articles 2022
Jan 3, 2022
Gene involved in sense of smell could play a role in the spread of breast cancer to the brain
Jan 4, 2022
Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness
Jan 14, 2022
The efficacy of pyrotinib-based therapy in lapatinib-resistant metastatic HER2-positive breast cancer
Jan 18, 2022
Tucatinib Added to Trastuzumab and Capecitabine for Pretreated HER2+ Metastatic Breast Cancer ± Brain Metastases
Jan 24, 2022
Targeting Brain Metastases in Breast Cancer
Jan 26, 2022
Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities
Jan 28, 2022
Researchers discover new way to target secondary breast cancer that has spread to the brain
Feb 3, 2022
Pyrotinib Plus Capecitabine for Patients With HER2-Positive Breast Cancer and Brain Metastases
Feb 15, 2022
Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
Feb 23, 2022
How to Incorporate Tucatinib Into HER2-Positive Metastatic Breast Cancer Treatment
Feb 25, 2022
Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program
March 1, 2022
‘Tremendous Hope’ Surrounds Emerging Therapies for Cancer That has Spread to the Brain
March 2, 2022
More Effective, Less Toxic Treatment Approach for Brain Metastases May Improve Care and Survival
March 5, 2022
Brain Metastases Are Now More Treatable in HER2+ Metastatic Breast Cancer
March 2, 20222
Dalpiciclib Combined With Pyrotinib and Letrozole in Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer (LORDSHIPS): A Phase Ib Study
March 8, 2022
p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases
March 9, 2022
Trastuzumab Deruxtecan Continues to Elicit Responses in HER2+ Breast Cancer With Active Brain Metastases
March 11, 2022
Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort
March 12, 2022
Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
March 15, 2022
Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
March 22, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
March 22, 2022
Central nervous system disease in phase III studies for advanced HER2 positive breast cancer: A review
March 22, 2022
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
April 7, 2022
Incidence and impact of brain metastasis in patients with hereditary BRCA1 or BRCA2 mutated invasive breast cancer
April 9, 2022
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases
April 22, 2022
Salvage brachytherapy for multiply recurrent metastatic brain tumors: A matched case analysis
May 5, 2022
Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases | PracticeUpdate
May 6, 2022
Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients
May 13, 2022
Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline | Journal of Clinical Oncology
May 22, 2022
Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
May 23, 2022
Clinical Factors and Association With Treatment Modalities in Patients With Breast Cancer and Brain Metastases who Develop Leptomeningeal Metastases
May 25, 2022
Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases
May 26, 2022
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
May 26, 2022
Trastuzumab-Deruxtecan in Patients With HER2-Positive Breast Cancer With Active Brain Metastases
May 26, 2022
Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial | Neuro-Oncology | Oxford Academic
May 31, 2022
Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update | Journal of Clinical Oncology
June 2, 2022
ASCO Guideline Update Aims to Improve Patient Outcomes for HER2-Positive Breast Cancer With Brain Metastases
June 13, 2022
Trastuzumab Deruxtecan in Patients With CNS Involvement From HER2+ Breast Cancer | PracticeUpdate
June 27, 2022
Proton Craniospinal Irradiation With Photon Involved-Field Radiotherapy for Solid Tumor Leptomeningeal Metastasis | PracticeUpdate
June 27, 2022
New Resource ‘Empowers’ Patients With Breast Cancer That Has Spread to the Brain With Much Needed Information
June 28, 2022
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
July 8, 2022
Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis
Aug 8, 2022
Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial | Nature Medicine
Aug 9, 2022
Trastuzumab Deruxtecan Shows High Intracranial Response Rate in Patients with Active Brain Metastases from HER2-Positive Breast Cancer
Aug 10, 2022
A phase I/II study of intrathecal trastuzumab in human epidermal growth factor receptor 2-positive (HER2-positive) cancer with leptomeningeal metastases: Safety, efficacy, and cerebrospinal fluid pharmacokinetics
Aug 12, 2022
Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada | Breast Cancer | JAMA Network Open | JAMA Network
Aug 22, 2022
Intrathecal Administration of Trastuzumab in Patients With HER2+ Breast Cancer With Leptomeningeal Metastasis | PracticeUpdate
Aug 22, 2022
Safety and Efficacy of Intrathecal Trastuzumab in HER2-Positive Cancer With Leptomeningeal Metastases | PracticeUpdate
Aug 23, 2022
Trastuzumab Deruxtecan in HER2-Positive Breast Cancer With Brain Metastases | PracticeUpdate
Oct 10, 2022
Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer
Oct 10, 2022
Strides Are Being Made in the Treatment of Brain Metastases From Breast Cancer – The ASCO Post
Oct 12, 2022
IMPACT the Brain: A Team-Based Approach to Management of Metastatic Breast Cancer With CNS Metastases | JCO Oncology Practice
Oct 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis | Cancer Discovery | American Association for Cancer Research
Nov 11, 2022
Incidence proportion and prognosis of leptomeningeal disease among patients with breast vs. non-breast primaries
Dec 1, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Dec 2, 2022
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain MetastasesUpdated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial
Dec 2, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
Brain Metastases Research Articles 2021
Jan 5, 2021
Breast Cancer Brain Metastases: Clinical Challenges and Recent Advancements
Jan 6, 2021
Updated ExteNET Data Raise Questions Over TKI Utility in HER2+ Breast Cancer With Brain Metastases
Jan 7, 2021
Leptomeningeal disease and neurologic death after surgical resection and radiosurgery for brain metastases: A multi-institutional analysis
Jan 7, 2021
A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature
Jan 8, 2021
A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
Jan 12, 2021
Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF
Feb 1, 2021
Stromal Platelet–Derived Growth Factor Receptor-β Signaling Promotes Breast Cancer Metastasis in the Brain | Cancer Research
Feb 2, 2021
Managing Patients With HER2+ Breast Cancer and Brain Metastasis: Slides
Feb 3, 2021
MiR-211 determines brain metastasis specificity through SOX11/NGN2 axis in triple-negative breast cancer
Feb 3, 2021
The Genomic Landscape of Breast Cancer Brain Metastases
Feb 12, 2021
Tucatinib Approved in Europe for Locally Advanced or Metastatic HER2+ Breast Cancer
Feb 18, 2021
Dual- versus single-agent HER2 inhibition and incidence of intracranial metastatic disease: a systematic review and meta-analysis
Feb 18, 2021
An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple negative breast cancer
Feb 23, 2021
A New Study Casts Doubt on Lab Models of the Blood Brain Barrier – Patient Worthy
March 2, 2021
Nancy Lin, MD, on Breast Cancer With Brain Metastasis
March 3, 2021
Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer
March 4, 2021
New Indications in HER2+ Breast Cancer Spark Discussions on Selection, Safety, and Sequencing
March 5, 2021
What’s New in HER2+ MBC Targeted Therapy: Efficacy Analysis of Oral HER2-TKIs Tucatinib & Neratinib | VuMedi
March 6, 2021
Research Moves Full Steam Ahead With Brain Metastases, Leptomeningeal Disease in Breast Cancer
March 8, 2021
Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment
March 10, 2021
Modern Approaches to Brain Cancer Metastases in Breast Cancer
March 18, 2021
Experts Take Stock of New CNS Data for HER2+ Metastatic Breast Cancer
March 19, 2021
Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases
March 20, 2021
2021 Update on Breast Cancer Brain Metastases: Current Treatment Options and Challenges
March 24, 2021
Immunotherapy Shows Promise for Treating Brain Metastases
April 1, 2021
Fatty acid synthesis is required for breast cancer brain metastasis
April 8, 2021
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations
May 4, 2021
Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study
May 12, 2021
Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer
May 20, 2021
Stereotactic Radiosurgery for Brainstem Metastases
May 27, 2021
Tumor Control and Risk of Radiation Necrosis Following Stereotactic Radiosurgery for Brain Metastasis
May 28, 2021
Usefulness of assessment of circulating tumor DNA(ctDNA) of cerebrospinal fluid(CSF) samples for early detection of brain metastasis (BrM) in patients with triple-negative breast cancer (TNBC)
June 2, 2021
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
June 5, 2021
Tucatinib Plus Trastuzumab/Capecitabine Maintain Survival Benefit in HER2-Positive Breast Cancer
June 8, 2021
Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases
June 15, 2021
2021 ASCO Updates on Systemic Chemotherapy in Patients With Brain Only MBC: A Retrospective Analysis
June 23, 2021
Surveying Efficacy Data of Tucatinib, Palbociclib and Letrozole Combination in Patients With HR+/HER2+ MBC | VuMedi
June 29, 2021
Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial)
July 5, 2021
Breast cancer brain metastasis: insight into molecular mechanisms and therapeutic strategies
July 8, 2021
A SNAI2-PEAK1-INHBA stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting subpopulations of tumor cells positive for antiapoptotic and stress signaling markers
July 13, 2021
Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases
July 15, 2021
Tucatinib in Combination with Trastuzumab and Capecitabine in HER2-Positive Metastatic Breast Cancer
July 21, 2021
Pyrotinib Treatment in Patients With HER2+ Metastatic Breast Cancer and Brain Metastasis
July 22, 2021
New approach eradicates breast cancer in mice
July 27, 2021
Advances in HER2+ MBC: Management of CNS Metastases | VuMedi
July 28, 2021
Genomic Landscape of Breast Carcinoma Brain Metastases
August 2021
Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Aug 1, 2021
Aging and CNS Myeloid Cell Depletion Attenuate Breast Cancer Brain Metastasis
Aug 4, 2021
Examining Recent Advances in the Management of Brain Metastases in HER2-Positive Breast Cancer
Aug 5, 2021
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
Aug 9, 2021
Detection of Leptomeningeal Disease Using Cell-Free DNA From Cerebrospinal Fluid
August 12, 2021
Trastuzumab Deruxtecan for HER2+ MBC With Brain Mets: DESTINY-Breast01 Trial Subgroup Analysis
Sept 8, 2021
Update from HER2CLIMB in Relapsed Refractory HER2-Positive Breast Cancer
Sept 9, 2021
Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer
Sept 14, 2021
A common goal to CARE: Cancer Advocates, Researchers, and Clinicians Explore current treatments and clinical trials for breast cancer brain metastases
Sept 14, 2021
Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
Sept 23, 2021
Different types of cancers are likely to spread to specific areas of the brain
Sept 25, 2021
A window into the care needs of patients with brain metastases
Oct 12, 2021
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis
Oct 13, 2021
MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases
Oct 28, 2021
Immune Checkpoint Inhibitors in Patients With Brain Metastasis
Oct 28, 2021
Patient-Reported Outcomes After a Diagnosis of Brain Metastasis
Nov 15, 2021
Novel prognostic classification predicts overall survival of patients receiving salvage whole-brain radiotherapy for recurrent brain metastasis from breast cancer: A recursive partitioning analysis (KROG 16-12)
Nov 19, 2021
Characterization of plasma circulating small extracellular vesicles in patients with metastatic solid tumors and newly diagnosed brain metastasis
Nov 21, 2021
SNO 2021: Ipilimumab + Nivolumab Appears Promising for Leptomeningeal Carcinomatosis
Nov 27, 2021
Advances in the management of breast cancer brain metastases
Nov 27, 2021
Surgical advances in the management of brain metastases
Nov 27, 2021
Laser interstitial thermal therapy for brain metastases
Nov 27, 2021
Special issue: advances in the multimodality management of brain metastases and ongoing approaches to further improve their treatment
Nov 27, 2021
Advances in radiotherapy for brain metastases
Nov 27, 2021
Advances in the diagnosis, evaluation, and management of leptomeningeal disease
Nov 27, 2021
Preservation of neurocognitive function in the treatment of brain metastases
Nov 27, 2021
The microenvironment of brain metastases from solid tumors
Nov 27, 2021
Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases
Nov 27, 2021
Animal models of brain metastasis
Nov 30, 2021
Pre-Conference Coverage: Miami Brain Symposium 2021 – Controversies in Metastasis Management
Nov 30, 2021
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases
Dec 2, 2021
SNO 2021: Neratinib Is Promising for Leptomeningeal Metastases of Heavily Pretreated HER2+ Breast Cancer
Dec 8, 2021
Tucatinib Plus Palbociclib/Letrozole Prolongs CNS-PFS in HR+/HER2+ Breast Cancer
Dec 21, 2021
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
Brain Metastases Research Articles 2020
Jan 15, 2020
Scientists breach brain barriers to attack tumors
Feb 3, 2020
Changing Paradigms in the Management of Brain Metastases
Feb 6, 2020
SABCS Showcased Novel Agents in the HER2+ Breast Cancer Armamentarium
Feb 14, 2020
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Feb 14, 2020
Neurocognitive Outcomes for Patients With Brain Metastasis in the Modern Era: Benefit of Treatment With Hippocampal Avoidance Whole-Brain Radiotherapy Plus Memantine
Feb 20, 2020
Current approaches to the management of brain metastases
Feb 20, 2020
Neoadjuvant Radiosurgery Shows Efficacy for Large Brain Metastases
March 2, 2020
Overcoming the Blood–Brain Barrier in the Management of Brain Tumors
March 3, 2020
Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study
March 7, 2020
Rugo Spotlights Potential With Tucatinib, Other Novel Agents in HER2+ Breast Cancer
March 16, 2020
Multidisciplinary patient-centered management of brain metastases and future directions
March 16, 2020
Emerging Data for Brain Metastases From HER2+ Breast Cancer
April 1, 2020
Clinical outcome of patients with brain metastases from breast cancer – A population based study over 21 years
April 9, 2020
Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases
May 6, 2020
Focused ultrasound opening brain to previously impossible treatments
May 14, 2020
AACR: Clinical Implications of Mutational Data From Brain Metastases
May 17, 2020
Cellular and Molecular Changes of Brain Metastases-Associated Myeloid Cells during Disease Progression and Therapeutic Response
May 18, 2020
Updates in HER2+ Metastatic Breast Cancer: HER2CLIMB
May 24, 2020
Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets
May 25, 2020
Frontiers | Effectiveness and Safety of Pyrotinib, and Association of Biomarker With Progression-Free Survival in Patients With HER2-Positive Metastatic Breast Cancer: A Real-World, Multicentre Analysis | Oncology
May 26, 2020
Identification of risk factors for central nervous system metastasis in patients with breast cancer with neurologic symptoms
May 27, 2020
Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
May 29, 2020
Dr. Lin on Updated Findings of HER2CLIMB Study in HER2+ Breast Cancer Brain Mets
June 1, 2020
Explore an available treatment option for patients with HER2+ metastatic breast cancer
June 1, 2020
Receptor Discordance in Breast Cancer Brain Metastases: When Knowledge is Power
June 2, 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
June 5, 2020
Sequencing Options Expand for Patients With HER2+ MBC and Brain Metastases
June 8, 2020
ASCO 2020: Immune Profiling of Tumor Microenvironment Predicts Overall Survival in Breast Cancer Brain Metastases
June 15, 2020
Rab11b-mediated integrin recycling promotes brain metastatic adaptation and outgrowth
June 30, 2020
HER2CLIMB: Brain Metastases Data
June 30, 2020
Treatment Choice for Patient Relapsing With Brain Metastases
June 30, 2020
Emerging treatment strategies for breast cancer brain metastasis: from translational therapeutics to real-world experience
June 30, 2020
DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer
July 4, 2020
Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial
July 13, 2020
Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
July 17, 2020
Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis
July 17, 2020
Metastatic HER2+ Breast Cancer Treatment Must Move to Personalized Approach
July 17, 2020
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial | Journal of Clinical Oncology
July 23, 2020
Cancer cells in brain and spinal fluid monopolize iron to survive
July 23, 2020
Liquid Biopsy Detects Brain Cancer and Early-Stage Kidney Cancer
July 23, 2020
T-DM1 in Patients With HER2-Positive Breast Cancer and Brain Metastases: KAMILLA Trial
Aug 2020
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Aug 4, 2020
Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype
Aug 17, 2020
Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study | Esmo Open
Aug 18, 2020
Cortisol promotes breast-to-brain metastasis through the blood-cerebrospinal fluid barrier
Aug 20, 2020
The Brain Microenvironment Induces DNMT1 Suppression and Indolence of Metastatic Cancer Cells
Aug 27,2020
New Therapy Targets Breast Cancer Metastases in Brain
Aug 27, 2020
Trastuzumab Deruxtecan, Tucatinib Generate Excitement in Metastatic HER2+ Breast Cancer
Aug 31, 2020
Targeting HER2 in Breast Cancer Patients With Brain Metastases
Sept 3, 2020
Intra-CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases
Sept 14, 2020
Stereotactic Radiosurgery in Combination With Anti-HER2 Therapy for HER2+ Breast Cancer Brain Metastases
Sept 15, 2020
Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient | Journal of Clinical Oncology
Sept 18, 2020
A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer
Sept 23, 2020
Novel breast cancer treatment ready for phase 3 trial
Sept 29, 2020
Intracranial Efficacy of Entrectinib Among Patients With NTRK Fusion-Positive CNS Metastases | PracticeUpdate
Oct 1, 2020
LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy
Oct 3, 2020
Survival in Patients With Brain Metastases
Oct 9, 2020
Scientists discover key gene driving breast cancer to the brain
Oct 14, 2020
HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
Oct 15, 2020
HSRT a Good Option for Resection Cavity of Brain Metastases
Oct 27, 2020
CNS-Native Myeloid Cells Drive Immune Suppression in the Brain Metastatic Niche through Cxcl10
Oct 30, 2020
Epigenetic targeting of neuropilin-1 prevents bypass signaling in drug-resistant breast cancer
Oct 31, 2020
ASTRO 2020: Addition of Immunotherapy to Radiation Improves Survival in Patients With Brain Metastases Initially Treated Surgically
Oct 31, 2020
ASTRO 2020: Cognition is Worsened More by Whole-brain Radiotherapy Than Stereotactic Radiosurgery for Brain Metastases
Oct 31, 2020
ASTRO 2020: Stereotactic Radiosurgery Superior to Whole-Brain Radiotherapy for Patients With Numerous Brain Metastases
Oct 31, 2020
ASTRO 2020: Study Fails to Demonstrate That Timing Between Planning MRI and Stereotactic Radiosurgery Affects Survival of Patients With Brain Metastases
Nov 12, 2020
Pembrolizumab Shows Intriguing Benefit in Leptomeningeal Metastasis From Solid Tumors
Nov 25, 2020
SNO 2020: Bevacizumab + Chemotherapy or Immune Checkpoint Inhibition ± Chemotherapy Can Reduce First or New Brain Metastases by 30%
Nov 25, 2020
SNO 2020: Lapatinib + WBRT/SRS Trends Toward Improvement of Brain Metastases From HER2+ Breast Cancer
Dec 2, 2020
Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China
Dec 8, 2020
Expert Panel Discussion on HER2+ MBC: What Are the RT Options for Brain Mets? | VuMedi
Dec 9, 2020
HIF1A signaling selectively supports proliferation of breast cancer in the brain
Dec 9, 2020
SABCS 2020: Benefits of Neratinib Over Lapatinib for Breast Cancer Appear Independent of Baseline Central Nervous System Metastases
Dec 16, 2020
2020 Top Stories in Brain Cancer: Hippocampal Avoidance WBRT Plus Memantine in Patients With Brain Metastases
Dec 17, 2020
2020 Top Stories in Metastatic Breast Cancer: Progress in Targeting a Sanctuary Site: Brain Mets in MBC
Dec 23, 2o20
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors
Brain Metastases Research Articles 2019
Jan 24, 2019
A blazing landscape: Neuroinflammation shapes brain metastasis
Feb 22, 2019
Estradiol induces BDNF/TrkB signaling in triple-negative breast cancer to promote brain metastases
Feb 26, 2019
Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice
April 17, 2019
A Phase II Trial of Concurrent Temozolomide and Hypofractionated Stereotactic Radiotherapy for Complex Brain Metastases
June 4, 2019
Advanced Magnetic Resonance Imaging Techniques in Management of Brain Metastases
June 9, 2019
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance | Oncogene
July 19, 2019
FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
July 29, 2019
Newer Treatments and Combinations Emerging for Breast Cancer Brain Metastases
Aug 16, 2019
Deep multiomics profiling of brain tumors identifies signaling networks downstream of cancer driver genes
Aug 23, 2019
Targeting the Sanctuary Site: Options when Breast Cancer Metastasizes to the Brain
Aug 23, 2019
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10 | Journal of Clinical Oncology
Sept 4, 2019
Current Drug Treatment Approaches for Brain Metastases
Sept 11, 2019
Current Radiation Treatment Approaches for Brain Metastases
Sept 11, 2019
Utilizing Multidisciplinary Immunotherapy Strategies in the Treatment of Solid Tumor Brain Metastases
Sept 27, 2019
Breast Cancer Brain Metastases: New Initial Therapy Options
Sept 19, 2019
Cancer Metastasis – Moving From Breast to Brain
Oct 1, 2019
Moffitt Launches Innovative Trial for Brain-Metastatic Breast Cancer | Moffitt
Oct 3, 2019
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers
Oct 14, 2019
High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature
Oct 31, 2019
Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16–12) – The Breast
Nov 29, 2019
Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis
Dec 1, 2019
Polyunsaturated Fatty Acids from Astrocytes Activate PPARγ Signaling in Cancer Cells to Promote Brain Metastasis
Dec 6, 2019
Proton Craniospinal Irradiation for Leptomeningeal Disease
Dec 8, 2019
Update on Immunotherapy and Targeted Therapy for Brain Metastases
Brain Metastases Research Articles 2018
June 9, 2018
IsoRay Announces FDA Clearance of GammaTile™ Therapy for the Treatment of Recurrent Brain Neoplasms
June 11, 2018
Examining the survival benefit of radiation therapy on leptomeningeal carcinomatosis and identifying factors associated with survival benefit of whole-brain radiation therapy
Oct 1, 2018
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry
Brain Metastases Research Articles 2017
June 26, 2017
Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer
Oct 2, 2017
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Brain Metastases Working Group
Oct 12, 2017
Colony stimulating factor-1 receptor as a treatment for cognitive deficits postfractionated whole-brain irradiation
Brain Metastases Research Articles 2016
July 25, 2016
Characteristics and outcomes of breast cancer patients with leptomeningeal metastasis
